FI941193A0 - IgE-välitteisten yliherkkyysreaktioiden hoitamiseksi tarkoitettu rokote, joka sisältää osan IgE:n vakioalueesta - Google Patents

IgE-välitteisten yliherkkyysreaktioiden hoitamiseksi tarkoitettu rokote, joka sisältää osan IgE:n vakioalueesta

Info

Publication number
FI941193A0
FI941193A0 FI941193A FI941193A FI941193A0 FI 941193 A0 FI941193 A0 FI 941193A0 FI 941193 A FI941193 A FI 941193A FI 941193 A FI941193 A FI 941193A FI 941193 A0 FI941193 A0 FI 941193A0
Authority
FI
Finland
Prior art keywords
ige
vaccine
pct
mediated
antibodies
Prior art date
Application number
FI941193A
Other languages
English (en)
Swedish (sv)
Other versions
FI107880B (fi
FI941193A (fi
Inventor
Lars T Hellman
Original Assignee
Lars T Hellman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20383848&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI941193(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lars T Hellman filed Critical Lars T Hellman
Publication of FI941193A publication Critical patent/FI941193A/fi
Publication of FI941193A0 publication Critical patent/FI941193A0/fi
Application granted granted Critical
Publication of FI107880B publication Critical patent/FI107880B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/80—Antibody or fragment thereof whose amino acid sequence is disclosed in whole or in part
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/801—Drug, bio-affecting and body treating compositions involving antibody or fragment thereof produced by recombinant dna technology
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/805—Drug, bio-affecting and body treating compositions involving IgE or IgD
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/809—Drug, bio-affecting and body treating compositions involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/862—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgE or IgD
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/867—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody produced via recombinant dna technology
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FI941193A 1991-09-26 1994-03-14 Menetelmä IgE-välitteisten yliherkkyysreaktioiden hoitamiseksi tarkoitetun rokotteen, joka sisältää osan IgE:n vakioalueesta, valmistamiseksi FI107880B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE9102808A SE9102808L (sv) 1991-09-26 1991-09-26 Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner
SE9102808 1991-09-26
PCT/SE1992/000673 WO1993005810A1 (en) 1991-09-26 1992-09-25 VACCINE COMPRISING PART OF CONSTANT REGION OF IgE FOR TREATMENT OF IgE-MEDIATED ALLERGIC REACTIONS
SE9200673 1992-09-25

Publications (3)

Publication Number Publication Date
FI941193A FI941193A (fi) 1994-03-14
FI941193A0 true FI941193A0 (fi) 1994-03-14
FI107880B FI107880B (fi) 2001-10-31

Family

ID=20383848

Family Applications (1)

Application Number Title Priority Date Filing Date
FI941193A FI107880B (fi) 1991-09-26 1994-03-14 Menetelmä IgE-välitteisten yliherkkyysreaktioiden hoitamiseksi tarkoitetun rokotteen, joka sisältää osan IgE:n vakioalueesta, valmistamiseksi

Country Status (16)

Country Link
US (1) US5653980A (fi)
EP (1) EP0666760B2 (fi)
JP (2) JP3583421B2 (fi)
KR (1) KR100263359B1 (fi)
AT (1) ATE189960T1 (fi)
AU (1) AU677573B2 (fi)
CA (1) CA2117193C (fi)
DE (1) DE69230733T3 (fi)
DK (1) DK0666760T4 (fi)
ES (1) ES2144424T5 (fi)
FI (1) FI107880B (fi)
GR (1) GR3033272T3 (fi)
HU (1) HU218899B (fi)
RU (1) RU2120805C1 (fi)
SE (1) SE9102808L (fi)
WO (1) WO1993005810A1 (fi)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK96493D0 (da) * 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
AU707083B2 (en) * 1993-08-26 1999-07-01 Bavarian Nordic Inc. Inducing antibody response against self-proteins with the aid of foreign T-cell epitopes
JP3825798B2 (ja) * 1994-01-18 2006-09-27 ジェネンテク，インコーポレイテッド ＩｇＥアンタゴニストを用いる寄生虫感染症の治療法
FR2715304B1 (fr) * 1994-01-26 1996-04-26 Merieux Serums Vaccins Pasteur Vaccin anti-allergique.
RU2193413C2 (ru) 1996-03-01 2002-11-27 Новартис Аг Пептидные иммуногены для вакцинации и лечения аллергии
SK285639B6 (sk) * 1997-04-15 2007-05-03 Pharmexa A/S Modifikovaná ľudská TNFalfa molekula, DNA kódujúce takéto TNFalfa molekuly, spôsob výroby modifikovanej ľudskej TNFalfa molekuly, vakcíny obsahujúce modifikované TNFalfa molekuly a DNA a ich použitie
US7393529B2 (en) 1998-04-09 2008-07-01 Idexx Laboratories, Inc. Methods and compositions for inhibiting binding of IgE to a high affinity receptor
US6504013B1 (en) 2000-02-01 2003-01-07 Idexx Laboratories, Inc. Canine allergy therapeutic recombinant chimeric anti-IgE monoclonal antibody
US6734287B1 (en) 1998-04-09 2004-05-11 Idexx Laboratories, Inc. Specific binding proteins for treating canine allergy
US6913749B2 (en) * 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
EP1621209A3 (en) * 1998-11-02 2006-04-19 Resistentia Pharmaceuticals AB Vaccines based on domains of chimeric immunoglobulin E peptides
US6511814B1 (en) 1999-03-26 2003-01-28 Idexx Laboratories, Inc. Method and device for detecting analytes in fluids
US6602719B1 (en) 1999-03-26 2003-08-05 Idexx Laboratories, Inc. Method and device for detecting analytes in fluids
EP2361635A3 (en) 2000-08-30 2011-09-14 Pfizer Products Inc. Anti IgE vaccines
JP2003047482A (ja) * 2001-05-22 2003-02-18 Pfizer Prod Inc 非アナフィラキシー誘発性ＩｇＥワクチン
EP1497654A4 (en) * 2001-08-13 2006-06-07 Chen Swey Shen Alex IMMUNOGLOBULIN E VACCINES AND METHODS OF USE
US7425620B2 (en) 2002-08-14 2008-09-16 Scott Koenig FcγRIIB-specific antibodies and methods of use thereof
ES2316780T3 (es) * 2002-09-05 2009-04-16 Resistentia Pharmaceuticals Ab Vacunas contra alergia.
US20050026881A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-IgE antibody for treatment of asthma or chronic obstructive pulmonary disease
US20090263381A1 (en) * 2003-07-31 2009-10-22 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease
ES2599319T3 (es) 2006-06-26 2017-02-01 Macrogenics, Inc. Anticuerpos específicos de Fc RIIB y métodos de uso de éstos
US20080118524A1 (en) * 2006-10-20 2008-05-22 Stefan Persson Anti-IgE Vaccines
SG186611A1 (en) 2008-12-09 2013-01-30 Pfizer Vaccines Llc Ige ch3 peptide vaccine
AU2010217100B2 (en) * 2009-02-25 2014-03-27 Academia Sinica Anti-CepsilonmX antibodies capable of binding to human mIgE on B lymphocytes
CA2800774A1 (en) 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
US9187553B2 (en) * 2012-01-25 2015-11-17 Swey-Shen Chen Displaying native human IgE neutralizing FcepsilonRIa-contacting IgE B-cell epitopes by constraining super beta(b)-strands and cystine knots on thermostable protein scaffold
CN104603150A (zh) 2012-04-20 2015-05-06 中央研究院 与CH4和CεmX结构域之间的连接处结合的抗mIgE抗体
JP5918851B2 (ja) * 2012-06-18 2016-05-18 日本全薬工業株式会社 ＩｇＥペプチドワクチン
US20150004161A1 (en) * 2013-07-01 2015-01-01 University Of Maryland Fc Coupled Compositions and Methods of Their Use
EP3703753A4 (en) 2017-10-31 2021-08-18 Oneness Biotech Co., Ltd. TREATMENT OF IGE-MEDIATED ALLERGIC DISEASES

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8616166D0 (en) * 1986-07-02 1986-08-06 Research Corp Ltd Polypeptide competitor
GB8727045D0 (en) * 1987-11-19 1987-12-23 Research Corp Ltd Immunoglobulin e competitor
DE122006000007I1 (de) * 1987-12-31 2006-04-27 Tanox Biosystems Inc Antigene epitope, die sich ausschlisslich auf ige-tragenden B-Lymphocyten befinden.
GB8910263D0 (en) * 1989-05-04 1989-06-21 Ciba Geigy Ag Monoclonal antibodies specific for an immunoglobulin isotype
GB8913737D0 (en) * 1989-06-15 1989-08-02 Univ Birmingham A novel anti-allergy treatment

Also Published As

Publication number Publication date
GR3033272T3 (en) 2000-09-29
AU677573B2 (en) 1997-05-01
EP0666760B2 (en) 2007-10-10
DK0666760T4 (da) 2008-01-21
FI107880B (fi) 2001-10-31
HUT69782A (en) 1995-09-28
JP2004231663A (ja) 2004-08-19
HU9400845D0 (en) 1994-06-28
WO1993005810A1 (en) 1993-04-01
CA2117193C (en) 2008-06-17
JPH06510768A (ja) 1994-12-01
JP3583421B2 (ja) 2004-11-04
ES2144424T5 (es) 2008-03-01
KR100263359B1 (ko) 2000-08-01
DK0666760T3 (da) 2000-07-31
ATE189960T1 (de) 2000-03-15
FI941193A (fi) 1994-03-14
EP0666760A1 (en) 1995-08-16
US5653980A (en) 1997-08-05
SE9102808D0 (sv) 1991-09-26
ES2144424T3 (es) 2000-06-16
RU2120805C1 (ru) 1998-10-27
DE69230733D1 (de) 2000-04-06
DE69230733T2 (de) 2000-08-03
EP0666760B1 (en) 2000-03-01
DE69230733T3 (de) 2008-05-21
HU218899B (hu) 2000-12-28
CA2117193A1 (en) 1993-04-01
SE9102808L (sv) 1993-03-27
AU2676592A (en) 1993-04-27

Similar Documents

Publication Publication Date Title
FI941193A0 (fi) IgE-välitteisten yliherkkyysreaktioiden hoitamiseksi tarkoitettu rokote, joka sisältää osan IgE:n vakioalueesta
King Chemical and biological properties of some atopic allergens
PT815235E (pt) Vacinas para peste
WO1996012794A3 (en) Isolated porcine pancreatic cells for use in treatment of diseases characterized by insufficient insulin activity
Gilhar et al. Transfer of alopecia areata in the human scalp graft/Prkdcscid (SCID) mouse system is characterized by a TH1 response
ATE122394T1 (de) Pankreatische isletzellen-antigene, erhalten durch molekulare klonierung.
Jones et al. A novel Fab-based antivenom for the treatment of mass bee attacks.
DK0482089T3 (da) Fremgangsmåder til behandling af autoimmun uveoretnitis i mennesker
Magro et al. Eosinophilic pustular follicular reaction: a paradigm of immune dysregulation
Grammer et al. Cutaneous allergy to human (recombinant DNA) insulin
DE69821506D1 (de) Verwendung einer chemisch stabilisierten chloritlösung zur inhibition der antigenspezifischen immunantwort
ES2319341T3 (es) Fragmentos tolerogenicos de alergenos naturales.
DE69032868D1 (de) Allergene proteine aus ambrosia und verwendung davon
ATE205531T1 (de) Lo-cd2a antikörper und dessen verwendung zur inhibition von t-zell-aktivierung und -wachstum
Gross et al. Isolation and partial characterization of the allergen in mountain cedar pollen
King Immunochemical studies of stinging insect venom allergens
REISMAN et al. Clinical and immunological studies of venom immunotherapy
DK0653939T3 (da) Anvendelse af en Hymenoptera-gift til fremstilling af et medikament til behandling af DNA-virusinfektioner
ES2124878T3 (es) Alergeno recombinante del polen del fleo $i (phl p) ii.
DE69330348D1 (de) Verwendung von Peptiden welche eine Immunantwort bewirken zur Herstellung von Medikamenten zur Induzierung der Immunsuppression.
Ruben Recombinant DNA produced human IL-2, injected in vivo, will substitute for carrier priming of helper function in the South African clawed toad, Xenopus laevis
DK0811067T3 (da) Equin arteritisviruspeptider, antistoffer og deres anvendelse i en diagnostisk test
DE69637943D1 (de) LO-CD2a Antikörper und deren Verwendung zur Hemmung der T-zellen Aktivierung und Proliferation
JP4085105B2 (ja) アレルギー疾患に対するペプチド免疫療法剤
Ishizaka Cellular mechanisms of IgE antibody response